Big RNAi Bucks: Alnylam, Roche Team Up in Drug Discovery Deal

FROM RNAi NEWS: The deal, worth up to $1 billion, also calls for Roche to acquire Alnylam’s German subsidiary, a financial burden the RNAi company has been required to shoulder as part of a 2002 licensing deal.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.